Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Investing Activities (2019 - 2025)

Benitec Biopharma's Cash from Investing Activities history spans 6 years, with the latest figure at -$6000.0 for Q1 2025.

  • For Q1 2025, Cash from Investing Activities rose 96.65% year-over-year to -$6000.0; the TTM value through Mar 2025 reached -$18000.0, up 89.94%, while the annual FY2024 figure was -$179000.0, 17800.0% down from the prior year.
  • Cash from Investing Activities for Q1 2025 was -$6000.0 at Benitec Biopharma, up from -$12000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $141000.0 in Q2 2021 and bottomed at -$179000.0 in Q1 2024.
  • The 4-year median for Cash from Investing Activities is -$12500.0 (2022), against an average of -$14000.0.
  • The largest annual shift saw Cash from Investing Activities soared 1184.62% in 2021 before it plummeted 109.22% in 2022.
  • A 4-year view of Cash from Investing Activities shows it stood at $141000.0 in 2021, then tumbled by 109.22% to -$13000.0 in 2022, then increased by 7.69% to -$12000.0 in 2024, then soared by 50.0% to -$6000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Cash from Investing Activities are -$6000.0 (Q1 2025), -$12000.0 (Q4 2024), and -$179000.0 (Q1 2024).